Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Exhibition > 2022 mAbTalk symposium: Emerging targets for immuno-oncology
  1. 2022 mAbTalk symposium: Emerging targets for immuno-oncology

    1. May 21, 2022, 8 p.m. (US EDT) | May 22, 2022, 8 a.m. (Beijing)
    2. Online
    3. Mitchell Ho, Senior Investigator, NCI; Dimiter Dimitrov, Professor, University of Pittsburgh
    Check more speaker details below.
    Click the button to enter our raffle.
  2. ACROBiosystems is proud to be the Gold Sponsor for 2022 mAbTalk symposium: Emerging targets for immuno-oncology


    With the development of biotechnology, immunotherapy has made significant progress and has become a novel cancer treatment. In particular, antibody therapies such as anti-CTLA-4 antibodies, anti-PD-1 antibodies, and anti-PD-L1antibodies have transformed certain cancers into chronic diseases.

    Despite people having great expectations for cancer immunotherapy, the development of immunotherapy has several challenges. For example, response rates to immunotherapy are quite low in tumors that have limited T-cell infiltration. Tumor cells can also escape immune system surveillance and develop drug resistance due to reduced mutational load (TMB). In addition, the tumor immunosuppressive microenvironment can make the treatment ineffective. These difficulties have caused concerns for cancer immunotherapy. However, breakthroughs have been made in the recent years.

    The first breakthrough was the combination therapy. The combination of the anti-CTLA-4 antibody Ipilimumab with the anti-PD-1 antibody Nivolumab has doubled the progression-free survival rate in metastatic melanoma patients. In addition, the combination of the anti-LAG-3 antibody Relatlimab and the anti-PD-1 antibody Nivolumab has increased progression-free survival by 50%, and reduced the side effects of the anti-CTLA-4 antibody by at least 50%. In fact, this combination strategy has revolutionized the first-line therapy for metastatic melanoma.

    Second, the emergence of new targets has also opened an entirely new field for cancer immunotherapy. The combination of the anti-PD-L1 antibody Tecentrip with the antibody targeting the new target TIGIT Tiragolumab has become the first-line treatment of non-small cell lung cancer. In patients with PD-L1 Tumor Proportion Score (TPS) ≥ 50%, this new therapy has increased the median progression-free survival of 4.1 months for the anti-PD-L1 antibody monotherapy to 16.6 months, and reduced the death rate by 71%. In addition, several T cell therapies, NK cell therapy, macrophage cell therapy, and T-reg cell therapies are in the clinical trials and may soon provide exciting outcomes.

    In view of the recent exciting development of cancer immunotherapy, the Chinese Antibody Society (CAS) and the CAS’s journal Antibody therapeutics will together hold the Chinese Antibody Society mAbTalkTM symposium with the title "Emerging Targets for Immuno-oncology" on Saturday, May 21, 2022, at 8:00 pm (US Eastern time) / Sunday, May 22 at 8:00 am (Beijing time). Several established academic experts in the field of immunotherapy will discuss various novel cancer immunotherapies.


    Meet the speakers



    Starts at 05/21/2022 8 p.m. (US EDT) | 05/22/2022 8 a.m. (Beijing)

    See Abstract

    05/21/2022 8:10 p.m. EDT

    Session 1 Glypicans as CART Targets in Solid Tumors

    Mitchell Ho, Senior Investigator, NCI

    See Abstract

    05/21/2022 8:40 p.m. EDT

    Session 1 FGL1 LAG3 as emergent target for immunotherapy of cancer and beyond

    Jun Wang, Assistant Professor, NYU

    See Abstract

    05/21/2022 9:10 p.m. EDT

    Session 1 RNA methylation in leukemogenesis and leukemia immunity

    Rui Su, Assistant Professor, City of Hope

    No abstract available

    05/21/2022 9:40 p.m. EDT

    Break acknowledgement to volunteers sponsor video

    Organizer, TBD, The Chinese Antibody Society

    See Abstract

    05/21/2022 10:10 p.m. EDT

    Session 2 Human VH domains against viruses and cancer

    Dimiter Dimitrov, Professor, University of Pittsburgh

    See Abstract

    05/21/2022 10:40 p.m. EDT

    Session 2 PP2A a novel immunotherapy target

    Rongze Lu, Assistant Professor, UT Austin UCSF

    See Abstract

    05/21/2022 11:10 p.m. EDT

    Session 2 Robust de novo design of protein binding proteins from target structural information alone

    Longxing Cao, Assistant Professor, Westlake University

    No abstract available

    05/21/2022 11:40 p.m. EDT

    Close Remarks

    Organizer, TBD, The Chinese Antibody Society


New & Hot Products

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message